Carmat (PAR: ALCAR)

Last close As at 18/03/2024

8.61

−0.08 (−0.92%)

Market capitalisation

EUR195m

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.

Latest Insights

View More

Healthcare | edison tv

Carmat: Edison Open House Healthcare 2022

Healthcare | Update

Carmat — Implantation momentum

Healthcare | edison tv

Carmat – Edison Open House interview

Healthcare | edison tv

Carmat – executive interview with Stéphane Piat

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (2.4) (21.8) (17.4)
Relative (7.4) (25.3) (27.4)
52 week high/low €14.8/€8.0

Financials

Edison Investment Research is terminating coverage on Carmat (ALCAR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2020A 0.0 N/A (38.7) (285.32) N/A N/A
2021A 2.2 N/A (61.9) (402.00) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

edison tv

Healthcare

Carmat – executive interview with Stéphane Piat

Update

Healthcare

Carmat — CE Mark achieved, launching in Q2

Update

Healthcare

Carmat — Development progressing in the US and EU

Outlook

Healthcare

Carmat — Full-year results and clinical updates

edison tv

Healthcare

Executive Interview – Carmat

Flash note

Healthcare

Carmat — Carmat obtains clearance to resume pivotal study

Flash note

Healthcare

Carmat — Update 1 December 2016

Further insights

insight

Healthcare

Total Artificial Hearts

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free